|1.||Offermann, Anne: 4 articles (10/2015 - 07/2014)|
|2.||Perner, Sven: 4 articles (10/2015 - 07/2014)|
|3.||Shaikhibrahim, Zaki: 4 articles (10/2015 - 07/2014)|
|4.||Vogel, Wenzel: 3 articles (04/2015 - 07/2014)|
|5.||Kristiansen, Glen: 2 articles (04/2015 - 07/2014)|
|6.||Braun, Martin: 2 articles (04/2015 - 07/2014)|
|7.||Schröck, Andreas: 1 article (04/2015)|
|8.||Lengerke, Claudia: 1 article (04/2015)|
|9.||Bootz, Friedrich: 1 article (04/2015)|
|10.||Mikut, Ralf: 1 article (04/2015)|
01/01/1993 - "All the other parameters evaluated (variation in pain intensity, peak of analgesic activity and total remission of pain) are significantly favorable to ST-679. "
01/01/1993 - "The evaluation of the evolution of pain, performed using the Scott-Huskisson visual analog scale, evidenced that the maximum analgesic efficacy of ST-679 is reached after 1 hour and 15 minutes from assumption and remains unaltered until the final observation (6 hours). "
01/01/1993 - "[An evaluation of the analgesic activity and tolerance of ST-679 in patients with pain following orthopedic and traumatological interventions]."
01/01/1993 - "The analgesic efficacy and tolerability of ST-679 (administered in a single oral dose of 1200 mg) was evaluated in a double-blind parallel-group study, as compared with paracetamol (administered in a single oral dose of 1000 mg) on 40 patients with pain following orthopedic or traumatological surgery. "
01/01/1993 - "The study, conducted on 40 patients with pain resulting from "minor" general surgery, for the purpose of evaluating the efficacy and tolerability of ST-679 (administered in a single oral dose of 1200 mg in 20 patients) and to compare them with those of paracetamol (administered in a single oral dose of 1000 mg in 20 patients), demonstrated that the new drug was active on all recorded parameters and superior to the reference drug. "
04/01/2015 - "MED15 overexpression in primary tumors from patients who developed recurrences was associated with higher mortality rates and occurred at highest frequency in oral cavity or oropharyngeal tumors. "
01/01/2015 - "While MED15 is absent or low in tumor-free testis and SEM, NSGCT highly express MED15, hinting at the diagnostic potential of this marker to distinguish between SEM and NSGCT. "
01/01/2015 - "In conclusion, MED15 is differentially expressed in tumor-free testis and TGCT. "
01/01/2015 - "In tumor-free seminiferous tubules, MED15 protein expression was absent or only low expressed in spermatogonia. "
01/01/2014 - "DNA Methylation at the Novel CpG Sites in the Promoter of MED15/PCQAP Gene as a Biomarker for Head and Neck Cancers."
10/01/2001 - "[Efficacy and safety of amtolmetin guacyl in the treatment of acute osteoarthritis]."
01/01/1993 - "[An evaluation of the therapeutic activity and tolerance of ST-679 in patients with osteoarthritis at different sites. "
01/01/1993 - "A multicentered study was carried out, under double-blind conditions, on 160 elderly patients afflicted with differently localized symptomatic osteoarthritis, for the purpose of evaluating the therapeutical efficacy and tolerability of ST-679 (per-os at a dose of 1200 mg pro die in 80 patients) and to compare them with those of tolmetin (per os at a dose of 1200 mg pro die in 80 patients). "
03/01/2000 - "The efficacy and tolerability of amtolmetin guacyl (AMG), a new non-steroidal anti-inflammatory drug, were compared with piroxicam, in patients with osteoarthritis. "
03/01/2000 - "Amtolmetin guacyl versus piroxicam in patients with osteoarthritis."
|4.||Prostatic Neoplasms (Prostate Cancer)
07/01/2014 - "MED15 expression and copy number/rearrangement status were assessed by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), respectively on 718 prostate cancer (PCa) specimens and sequenced by Sanger on a subset. "
07/01/2014 - "In this study, we investigated whether the mediator subunit MED15 is implicated in castration-resistant prostate cancer (CRPC). "
04/01/2015 - "The mediator subunit MED15 is essential for transforming growth factor (TGF)-β signaling and involved in breast and prostate cancers. "
07/01/2014 - "MED15, encoding a subunit of the mediator complex, is overexpressed at high frequency in castration-resistant prostate cancer."
01/01/2015 - "MED15 is part of the multiprotein Mediator complex which presents an integrative hub for transcriptional regulation and is known to be deregulated in several malignancies, such as prostate cancer and bladder cancer role, whereas the role of the Mediator complex in TGCT has not been investigated so far. "
|5.||Rheumatic Diseases (Rheumatism)
01/01/1993 - "[A clinical study to determine the optimal dosage of ST-679 in the treatment of rheumatic diseases]."
06/01/1999 - "A total of 64 patients aged 18-80 years, suffering from rheumatoid arthritis for more than 6 months and American Rheumatism Association functional class I, II or III were randomized in a double blind manner to amtolmetin guacyl or diclofenac for 4 weeks. "
|1.||Diclofenac (SR 38)
|3.||N-acetyltalosaminuronic acid (NAT)
|4.||Tolmetin (Tolmetin Sodium)
|9.||p38 Mitogen-Activated Protein Kinases
|2.||Gynecologic Surgical Procedures (Gynecologic Surgery)